跳至主要内容
临床试验/NCT05073172
NCT05073172
撤回
不适用

A Randomized Intra-Patient Controlled Study of StrataXRT ® Versus Current Practice to Prevent and Treat Radiation Dermatitis

OHSU Knight Cancer Institute1 个研究点 分布在 1 个国家2024年1月1日

概览

阶段
不适用
干预措施
Silicone-based Film Forming Topical Gel
疾病 / 适应症
Breast Carcinoma
发起方
OHSU Knight Cancer Institute
试验地点
1
主要终点
Radiation dermatitis
状态
撤回
最后更新
去年

概览

简要总结

This clinical trial studies the effect of StrataXRT in preventing and treating radiation dermatitis in breast cancer or head and neck cancer patients. Radiotherapy is often associated with multiple side effects. These side effects can cause patient injury and make it difficult to complete treatment. For example, radiation dermatitis or skin damage may result in severe skin peeling and skin irritation. Depending on the location of radiation, the skin damage can cause problems and be tough to heal. This trial aims to see whether StrataXRT may help to prevent dermatitis after radiation therapy.

详细描述

PRIMARY OBJECTIVE: I. Compare efficacy of silicone-based film forming topical gel (StrataXRT) versus (vs.) standard of care skin maintenance. SECONDARY OBJECTIVES: I. Evaluate overall effectiveness of StrataXRT. II. Evaluate post-radiation therapy (RT) recovery time for StrataXRT compared to standard of care. EXPLORATORY OBJECTIVES: I. To assess patient reported outcomes. II. Evaluate cost of StrataXRT for management of radiation dermatitis compared to standard of care skin maintenance. III. Evaluate the reduction in RT interruption/extension of overall duration of receiving RT based on the reduced skin toxicity. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients apply StrataXRT topically to the affected area once or twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =\< 1. ARM II: Patients receive standard of care including calendula and/or petrolatum-mineral oil-lanolin-ceresin ointment (Aquaphor) applied 2-6 times daily plus hydrogel or silver sulfadiazine (Silvadene) or topical corticosteroids applied twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =\< 1. After completion of study, patients are followed up at 6 days and 3 weeks post-RT.

注册库
clinicaltrials.gov
开始日期
2024年1月1日
结束日期
2025年7月1日
最后更新
去年
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Principal Investigator
主要研究者

Josh Walker, M.D., Ph.D.

Principal Investigator

OHSU Knight Cancer Institute

入排标准

入选标准

  • Patients will be adult (\> age of 18) patients. Both men and women and members of all races and ethnic groups will be included
  • Histologically confirmed malignancy for which standard curative measures in conjunction with radiotherapy are indicated to the following sites: whole breast/chest-wall for post-surgical radiotherapy or bilateral neck (levels one through six) for head and neck cancer
  • All head and neck cancer patients should have the left and right neck treated to the same dose when receiving bilateral neck irradiation
  • Ability to understand and the willingness to sign a written informed consent document

排除标准

  • Clinically evident skin involvement of malignancy
  • Thin patients with nodal involvement requiring bolus
  • Patients with significant unshaven facial or chest wall hair compromising film application
  • Evidence of active cellulitis or wound infection involving anticipated treatment site
  • History of prior radiotherapy to involved site within 5 cm of anticipated treatment field
  • Eastern Cooperative Oncology Group (ECOG) performance status \>= 3
  • Patients receiving concurrent capecitabine
  • Patient with skin grafts over treatment site(s)
  • Presence of psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. (i.e. schizophrenia, autism, temporary housing during treatment, scheduling conflict immediately after treatment. This will need to be assessed prior to consent
  • Actual or perceived inability to reliably apply StrataXRT to the patients treatment field in the home environment

研究组 & 干预措施

Arm I (StrataXRT)

Patients apply StrataXRT topically to the affected area once or twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =\< 1.

干预措施: Silicone-based Film Forming Topical Gel

Arm II (standard of care)

Patients receive standard of care including calendula and/or Aquaphor applied 2-6 times daily plus hydrogel or Silvadene or topical corticosteroids applied twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =\< 1.

干预措施: Calendula Ointment

Arm II (standard of care)

Patients receive standard of care including calendula and/or Aquaphor applied 2-6 times daily plus hydrogel or Silvadene or topical corticosteroids applied twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =\< 1.

干预措施: Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment

Arm II (standard of care)

Patients receive standard of care including calendula and/or Aquaphor applied 2-6 times daily plus hydrogel or Silvadene or topical corticosteroids applied twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =\< 1.

干预措施: Polyethylene Glycol Hydrogel

Arm II (standard of care)

Patients receive standard of care including calendula and/or Aquaphor applied 2-6 times daily plus hydrogel or Silvadene or topical corticosteroids applied twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =\< 1.

干预措施: Silver Sulfadiazine

Arm II (standard of care)

Patients receive standard of care including calendula and/or Aquaphor applied 2-6 times daily plus hydrogel or Silvadene or topical corticosteroids applied twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =\< 1.

干预措施: Topical Hydrocortisone

结局指标

主要结局

Radiation dermatitis

时间窗: Day 0 post-radiation therapy (RT)

Will be assessed by Common Terminology Criteria for Adverse Events (CTCAE).

次要结局

  • Grade 2+ radiation dermatitis(Day 6 +/- 1 post-RT)
  • Weekly Common Terminology Criteria for Adverse Events (CTCAE) scores(Up to week 3 post-RT)
  • Time to peak Common Terminology Criteria for Adverse Events (CTCAE) score(Up to week 3 post-RT)
  • Post-RT recovery time (to grade =< 1 radiation dermatitis(Up until entire irradiated treatment site healed (grade =< 1 dermatitis))

研究点 (1)

Loading locations...

相似试验